• Home
  • NEW DAY MEDICINE
  • 3 (77) 2025
  • 119 -3 (77) 2025 - I.R. Agababyan, N.G. Nizamova - STUDY ON THE EFFICACY OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE: OUTCOMES FROM THE SAMARKAND REGION CARDIOLOGY CENTER (2023-2024)

119 -3 (77) 2025 - I.R. Agababyan, N.G. Nizamova - STUDY ON THE EFFICACY OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE: OUTCOMES FROM THE SAMARKAND REGION CARDIOLOGY CENTER (2023-2024)

STUDY ON THE EFFICACY OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE: OUTCOMES FROM THE SAMARKAND REGION CARDIOLOGY CENTER (2023-2024)

I.R. Agababyan - Samarkand State Medical University

N.G. Nizamova - Samarkand State Medical University

Resume

Actuality: Heart failure with reduced ejection fraction (HFrEF) is a significant health concern, with right ventricular dysfunction (RVD) being a key predictor of poor outcomes. Sacubitril/valsartan has shown promise in improving left ventricular function, but its effects on RV-PA coupling and liver function remain underexplored, especially in the Central Asian population. This study evaluates its impact on patients with HFrEF in the Samarkand region. Objective: This study evaluates the effects of sacubitril/valsartan on right ventricular-pulmonary artery (RV-PA) coupling and liver function, measured by the albumin-bilirubin (ALBI) score, in heart failure patients with reduced ejection fraction (HFrEF). Materials and methods: A prospective observational study was performed at the Samarkand Region Cardiology Center from January 2023 to December 2024, involving 65 HFrEF patients with right ventricular dysfunction. Inclusion criteria included adults >18 еars, NYHA class II- IV, and LVEF ≤40% initiating sacubitril/valsartan therapy. Exclusions were severe valvular disease, primary right ventricular cardiomyopathy, acute coronary syndromes, and life-threatening conditions. Results: After one еar, sacubitril/valsartan treatment led to significant improvements: TAPSE (tricuspid annular plane systolic excursion) increased from 15.1 ± 1.8 mm to 18.3 ± 2.1 mm (p < 0.001), PASP (pulmonary artery systolic pressure) decreased from 46.2 ± 7.4 mmHg to 39.5 ± 6.8 mmHg (p < 0.001), and the ALBI score improved from -2.40 ± 0.35 to -2.52 ± 0.31 (p < 0.01). NT-proBNP levels decreased from 3000 ± 800 pg/mL to 1500 ± 600 pg/mL (p < 0.001), with 40% of patients improving in NYHA class. Conclusion: Sacubitril/valsartan significantly improves RV function, lowers pulmonary artery pressure, and enhances liver function in HFrEF patients. Further studies with larger cohorts are needed to confirm these findings.

Keywords: Sacubitril/valsartan, heart failure, right ventricular function, pulmonary artery, ALBI score.

First page

675

Last page

683

For citation:I.R. Agababyan, N.G. Nizamova - STUDY ON THE EFFICACY OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE: OUTCOMES FROM THE SAMARKAND REGION CARDIOLOGY CENTER (2023-2024)//New Day in Medicine 3(77)2025 675-683 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Bandera, F., et al. (2017). Mitral regurgitation in heart failure: Insights from CPET combined with exercise echocardiography. https://doi.org/10.1093/ehjci/jew096
  2. Cohn, J. N., et al.. (1997). "Cardiac dysfunction in heart failure: the role of the right ventricle." European Heart Journal, 1997;18(Supplement R):3-8.
  3. Gupta, N., et al. (2019). "Tricuspid annular plane systolic excursion and its correlation with right ventricular function in heart failure." // Cardiology Journal, 2019;26(5):578-586.
  4. Jiang, J., et al. (2016). "Hepatic dysfunction in patients with chronic heart failure: a review." Heart Failure Reviews, 2016;21(1):83-92.
  5. Kawut S. M., et al. (2015). "Right ventricular function and survival in heart failure with preserved ejection fraction." Journal of the American College of Cardiology, 2015;65(12):1177-1186.
  6. Kumar, A., et al. (2019). "Liver function in heart failure." European Journal of Heart Failure, 2019;21(4):475-482.
  7. López-Sendón, J., Swedberg, K., McMurray, J. (2013). "The importance of pulmonary hypertension in heart failure." European Heart Journal, 2013;34(49):3637-3645.
  8. McMurray, J. J. V., et al. (2012). "Heart failure epidemiology." European Heart Journal, 2012;33(16):2004-2010.
  9. McMurray, J. J. V., et al.. (2014). "Angiotensin-neprilysin inhibition versus enalapril in heart failure." New England Journal of Medicine, 2014;371(11):993-1004.
  10. McMurray, J. J., Packer, M. (2019). From heart failure with reduced ejection fraction to heart failure with preserved ejection fraction: the evolution of an old disease. European Heart Journal 2019;40(40):3280-3281.
  11. Nakamura K., et al.. (2016). "The albumin-bilirubin score predicts prognosis in patients with heart failure." Internal Medicine 2016;55(1):53-58.
  12. Varma N., et al. (2016). "Quality of life in heart failure: implications for clinical practice." Current Heart Failure Reports 2016;13(6):173-180.
  13. Zhamolotnov D., et al. (2021). "Economic burden of coronary artery disease in the Samarkand region." Journal of Cardiology and Cardiovascular Medicine 2021;5(2):10-17.

    file

    download